Navigation Links
Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
Date:7/25/2011

CINCINNATI, July 25, 2011 /PRNewswire/ -- Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Mefenamic Acid Capsules, USP 250 mg, the Authorized Generic version of Ponstel®. Prasco intends to begin shipping product immediately in the U.S. under the Prasco label.

"With the introduction of the authorized generic of Shionogi's PONSTEL®, Prasco continues to be the preferred partner for established brand companies to transcend their brands with our Authorized Generics," said Prasco Chief Executive Officer E. Thomas Arington. "We are pleased to have established this relationship with Shionogi Inc., a company that has been providing innovative medicines essential to people's health."

Prasco is the leading Authorized Generics company having brought more Authorized Generics to market than any other company. Prasco Authorized Generics are identical to the NDA brand product. Prasco partners with established brand companies to bring their products to the generics marketplace as Authorized Generics, which offers alternatives for consumers and pharmacists.

Mefenamic Acid Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Ponstel. For additional important information, please click here to see the Full Prescribing Information, INCLUDING BOXED WARNING.

Ponstel® is a registered trademark of Shionogi Inc.

About Prasco Laboratories

Prasco is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics.  Prasco Authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit www.prasco.com.  

CONTACT:  Kimberly A. Carroll
Advisor to the Chairman,
Corporate Marketing & Communications
k.carroll@prasco.com
513.204.1277
513.550.1473 C
Website:  www.prasco.com


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... April 18, 2017  Astute Medical, Inc., developer of ... to be presented at the 2017 National Kidney Foundation ... and continues through April 22. Physicians will present data ... to assess risk for acute kidney injury (AKI) during ... (ADHF). Elevated levels of TIMP-2 and ...
Breaking Medicine Technology:
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... A Week of Addiction and Recovery Education, from April 24 to April 28, ... substance use disorders. , The mission of AWARE is to instill a ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway Management, the ... with the highly regarded and well renowned Asian distributor, Discovery Sleep. ... PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence with a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... Enterprise in the category of International Trade, the UK’s most prestigious award for ... trade, which represents 95% of total revenues and has grown by a total ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones before ... planning process, or where to even begin. “Now more than ever there are some ... properly protect yourself and your family,” said attorney Lisa Edgar Dickman, founder of the ...
Breaking Medicine News(10 mins):